Physician profile
Mark A Smith
NPI 1720086358
$1,046.45
in general payments reported to CMS, 2019-2025
9 companies · $84.81 in 2025
The $84.81 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $71.10 · 2021: $32.67 · 2022: $62.77 · 2023: $134 · 2024: $166 · 2025: $84.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $385.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $275.29 | 2019-2022 | |
| Janssen Biotech, INC. | $238.21 | 2023-2025 | Tremfya, Stelara |
| Echosens North America, INC. | $200.50 | 2019 | |
| Abbvie INC. | $163.22 | 2019-2023 | Rinvoq, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $85.57 | 2019 | |
| Abiomed | $29.22 | 2024 | Impella |
| Braintree Laboratories, INC. | $27.58 | 2023 | Sutab |
| Celgene Corporation | $13.58 | 2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $13.28 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.